Render Target: STATIC
Render Timestamp: 2024-11-22T11:02:15.951Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-11-08 06:01:07.328
Product last modified at: 2024-11-19T14:00:10.551Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a
  1. Products /
  2. Primary Antibodies /
  3. NF-κB p65 Antibody Sampler Kit

NF-κB p65 Antibody Sampler Kit #4767

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    The NF-κB p65 Antibody Sampler Kit contains reagents to examine NF-κB p65/RelA phosphorylation at Ser468 and Ser536; acetylation at Lys310; and total p65 levels.

    Specificity / Sensitivity

    The total NF-κB p65 antibodies recognize endogenous levels of p65 regardless of post-translational modification state such as phosphorylation or acetylation. The phospho-NF-κB p65 antibodies recognize endogenous levels of p65 only when phosphorylated at their indicated target residues. The Acetyl-NF-κB p65 (Lys310) (D2S3J) Rabbit mAb recognizes transfected levels of p65 only when acetylated at Lys310.

    Source / Purification

    The NF-κB p65 (L8F6) Mouse mAb was produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human NF-κB p65. The Acetyl-NF-κB p65 (Lys310) (D2S3J) Rabbit mAb was produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys310 of human NF-κB p65 protein. The NF-κB p65 Antibody was produced by immunizing rabbits with a synthetic peptide corresponding to amino acids surrounding Glu498 of human NF-κB p65. The phospho-specific antibodies were produced by immunizing rabbits with synthetic phosphopeptides corresponding to amino acids surrounding the indicated target residues of human NF-κB p65. Polyclonal antibodies were purified by protein A and peptide affinity chromatography.

    Background

    Transcription factors of the nuclear factor κB (NF-κB)/Rel family play a pivotal role in inflammatory and immune responses (1,2). There are five family members in mammals: RelA, c-Rel, RelB, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). Both p105 and p100 are proteolytically processed by the proteasome to produce p50 and p52, respectively. Rel proteins bind p50 and p52 to form dimeric complexes that bind DNA and regulate transcription. In unstimulated cells, NF-κB is sequestered in the cytoplasm by IκB inhibitory proteins (3-5). NF-κB-activating agents can induce the phosphorylation of IκB proteins, targeting them for rapid degradation through the ubiquitin-proteasome pathway and releasing NF-κB to enter the nucleus where it regulates gene expression (6-8). NIK and IKKα (IKK1) regulate the phosphorylation and processing of NF-κB2 (p100) to produce p52, which translocates to the nucleus (9-11).
    RelA/p65 is a subunit of the NF-κB transcription complex, which plays a crucial role in inflammatory and immune responses. The complex is composed of various homodimeric and heterodimeric Rel family member combinations, the activity of which is modulated by post-translational modifications including phosphorylation and acetylation. p65 phosphorylation by PKA and/or MSK1 at Ser276 allows for increased interaction with the transcriptional coactivator p300/CBP to enhance transcriptional activity. NF-κB dimer assembly with IκB, as well as its DNA binding and transcriptional activities, are regulated by p300/CBP acetyltransferases that principally target Lys218, Lys221 and Lys310 (12-14). This process is reciprocally regulated by histone deacetylases (HDACs); several HDAC inhibitors have been shown to activate NF-κB (12-14). T-cell co-stimulation and Calyculin A have both been shown to increase Ser468 phosphorylation (15,16). IKKβ (but not IKKα) and GSK-3β both target this site (16,17), which appears to have a negative regulatory role not involving inhibition of nuclear translocation after TNF-α or IL-1β stimulation (17). p65 phosphorylation at Ser536 regulates activation, nuclear localization, protein-protein interactions, transcriptional activity, and apoptosis (18-22).
    1. Baeuerle, P.A. and Henkel, T. (1994) Annu Rev Immunol 12, 141-79.
    2. Baeuerle, P.A. and Baltimore, D. (1996) Cell 87, 13-20.
    3. Haskill, S. et al. (1991) Cell 65, 1281-9.
    4. Thompson, J.E. et al. (1995) Cell 80, 573-82.
    5. Whiteside, S.T. et al. (1997) EMBO J 16, 1413-26.
    6. Traenckner, E.B. et al. (1995) EMBO J 14, 2876-83.
    7. Scherer, D.C. et al. (1995) Proc Natl Acad Sci USA 92, 11259-63.
    8. Chen, Z.J. et al. (1996) Cell 84, 853-62.
    9. Senftleben, U. et al. (2001) Science 293, 1495-9.
    10. Coope, H.J. et al. (2002) EMBO J 21, 5375-85.
    11. Xiao, G. et al. (2001) Mol Cell 7, 401-9.
    12. Ashburner, B.P. et al. (2001) Mol Cell Biol 21, 7065-77.
    13. Mayo, M.W. et al. (2003) J Biol Chem 278, 18980-9.
    14. Chen, L.F. et al. (2002) EMBO J 21, 6539-48.
    15. Mattioli, I. et al. (2004) Blood 104, 3302-4.
    16. Buss, H. et al. (2004) J Biol Chem 279, 49571-4.
    17. Schwabe, R.F. and Sakurai, H. (2005) FASEB J 19, 1758-60.
    18. Doyle, S.L. et al. (2005) J Biol Chem 280, 23496-501.
    19. Sasaki, C.Y. et al. (2005) J Biol Chem 280, 34538-47.
    20. Mattioli, I. et al. (2004) J Immunol 172, 6336-44.
    21. Bae, J.S. et al. (2003) Biochem Biophys Res Commun 305, 1094-8.
    22. Buss, H. et al. (2004) J Biol Chem 279, 55633-43.

    Database Links

    UniProt ID: Q04206


    Entrez-Gene Id: 5970


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.